DxD Hub

ASSURE®

Produces cardiac risk assessment within 5 minutes, allowing clinicians to treat high - risk patients immediately. Superior to the TIMI and MEWS scores – the gold standards assessments currently used in clinical settings. Shortens triaging time from 1 - 2 hours to 5 minutes, with high-risk patients getting the timely intervention that is needed.

Employs a lateral flow format similar to those used in home pregnancy tests, thus allowing it to be deployed at the point of patient care.
Accurate results obtained in as little as 15 minutes.

ASSURE®

Produces cardiac risk assessment within 5 minutes, allowing clinicians to treat high - risk patients immediately. Superior to the TIMI and MEWS scores – the gold standards assessments currently used in clinical settings. Shortens triaging time from 1 - 2 hours to 5 minutes, with high-risk patients getting the timely intervention that is needed.

Employs a lateral flow format similar to those used in home pregnancy tests, thus allowing it to be deployed at the point of patient care.
Accurate results obtained in as little as 15 minutes.

cPass™

cPass™ is the world’s first SARS-CoV-2 serology test that allows rapid detection of functional neutralising antibodies (NAbs) present in the serum of COVID-19 patients. It was co-developed with Duke-NUS and GenScript.

Does not require live biological materials and biocontainment facility.
Can be rapidly conducted within an hour in most research or clinical labs and is also amenable to high throughput and fully automated testing after minimal adaptation.
Used in current covid-19 investigations, from contact tracing to determining infection rates, herd immunity and predicted humoral protection.

Fortitude 2.0

Fortitude 2.0 is one of the first few regulatory authorised COVID-19 molecular diagnostics in the world. It is first SARS-CoV-2 assay approved by HSA for clinical use to detect the presence of the SARS-CoV-2 virus quickly and accurately. The product was manufactured by and subsequently licensed to MiRXES. It was co-developed with Experimental Drug Development Centre (EDDC) from A*STAR, and Tan Tock Seng Hospital (TTSH).

Detected 100% of the positive samples tested at TTSH, with no reported false positive and false negative.
Targets the portion of the virus genome that is less prone to mutation, thus enabling robust detection of the virus.
Implemented in 13 Singapore public and private hospitals and labs since February 2020 and has been deployed in more than 45 countries globally.

GASTROClear

GASTROClear is the world’s first approved microRNA blood test for early detection of gastric cancer offered in ClinLab. It was co-developed with MiRXES, Singapore Gastric Cancer Consortium (SGCC), National University Hospital (NUH), and Tan Tock Seng Hospital (TTSH).

High performance test which detected 87.5% of stage I gastric cancers and 89.5% of stage II gastric cancers in clinical validation.
Minimally invasive procedure which requires only 5 millilitres of patient’s blood.
An actionable diagnostic test for cancer screening which gives a quantitative risk score and classifies each patient into a risk group.

Laennec®

Laennec® is the world’s first stain-free digital pathology imaging system to be approved for use in a clinical diagnosis of liver fibrosis and other chronic liver diseases. It was co-developed with HistoIndex and Singapore General Hospital (SGH).

Does not require staining of tissues which allows for preservation of tissue integrity.
Accurately diagnose the stage of liver fibrosis by enabling automatic assessment of tissue slides.

Respiree Monitor

Respiree monitor is a wearable wireless device that monitors COVID-19 patients by predicting worsening conditions. It was co-developed with Respiree and Singapore Bioimaging Consortium (SBIC).

Allows for comfortable wearing without sticking to skin.
Measures vital signs and trends to provide a risk score, thus predicting health deterioration.

aiTRIAGE™

aiTRIAGE™ is a SaMD using (clinical-based) machine learning algorithm to assist clinicians in quickly and accurately triaging patients at risk of Major Adverse Cardiac Event (MACE). It is currently in development with TIIM Healthcare (SGH and NHIC).

WHAT WE DO

Success Stories

COVID-19 Stories

miRNA

ASSURE®

ASSURE®

cPass™

Fortitude 2.0

GASTROClear

Read More

Laennec®

Digital Health

Respiree Monitor

Read More

aiTRIAGE™

Read More

COMPANY

SERVICES

RESOURCES